Dickkopf家族蛋白在非小细胞肺癌中的作用机制和治疗应用的研究进展

doi:10.11904/j.issn.1002-3070.2021.01.013

Abstract

Abstract: Non-small cell lung cancer(NSCLC)accounts for 80% to 85% of all lung cancers,and it is a malignant tumor with extremely high morbidity and mortality over the world.Initially,NSCLC has responded well to existing treatments,but it eventually has developed resistance.Therefore,it is necessary to explore effective and novel treatment methods.With the in-depth study of NSCLC,it is found that Dickkopf family protein(DKKs)signaling plays an important role in the development of NSCLC.DKKs are important regulators of the Wnt/β-catenin signaling pathway and are closely related to proliferation,metastasis and invasion of NSCLC cells.This article mainly introduces the mechanism of DKKs family members in NSCLC,discusses the potential of DKKs in the treatment of NSCLC,and provides new ideas for the further prevention and treatment of NSCLC.

Key words: Non-small cell lung cancer, Dickkopfs family proteins(DKKs), Wnt/β-catenin pathway

CLC Number:

R734.2

DONG Cheng,DUAN Yong. Research progress on the mechanism and treatment of Dickkopf family protein in non-small cell lung cancer[J]. Journal of Practical Oncology, 2021, 35(1): 64-68.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.01.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I1/64

References

1 Bozinovski S,Vlahos R,Anthony D,et al.COPD and squamous cell lung cancer:aberrant inflammation and immunity is the common link[J].Br J Pharmacol,2016,173(4):635-648.
2 Herbst RS,Morgensztern D,Boshoff C.The biology and management of non-small cell lung cancer[J].Nature,2018,553(7689):446-454.
3 蔡静,候玥.非小细胞肺癌患者血清miR-195的表达及其临床意义[J].实用肿瘤学杂志,2018,32(5):415-419.
4 黄本林,段勇.免疫检查点抑制剂在小细胞肺癌治疗中的临床研究进展[J].中国肺癌杂志,2019,22(4):239-244.
5 Yeung K,Carlson JJ.Clinical and economic review of erlotinib in non-small-cell lung cancer[J].Expert Rev Pharmacoecon Outcomes Res,2012,12(4):411-423.
6 Hirsch FR,Suda K,Wiens J,et al.New and emerging targeted treatments in advanced non-small-cell lung cancer[J].Lancet,2016,388(10048):1012-1024.
7 Heymach J,Krilov L,Alberg A,et al.Clinical cancer advances 2018:annual report on progress against cancer from the American society of clinical oncology[J].J Clin Oncol,2018,36(10):1020-1044.
8 Song Z,Wang H,Zhang S.Negative regulators of Wnt signaling in non-small cell lung cancer:theoretical basis and therapeutic potency[J].Biomed Pharmacother,2019,118,109336.
9 姚伶俐.DKK1在非小细胞肺癌血管生成拟态形成中的作用研究[D].天津:天津医科大学,2014.
10 Veeck J,Dahl E.Targeting the Wnt pathway in cancer:the emerging role of Dickkopf-3[J].Biochim Biophys Acta,2012,1825(1):18-28.
11 谢兰丰,沈思兰,钱方兴.Wnt信号通路抑制剂Dickkopf-3的研究进展[J].肝脏,2018,23(10):925-928.
12 张艳萍,刘昊凌.DKK1在糖尿病血管病变中的研究进展[J].医学综述,2017,23(15):3068-3071.
13 Gao Y,Du X,Zeng J,et al.Prediction and identification of transcriptional regulatory elements at the lung cancer-specific DKK1 locus[J].Oncol Lett,2018,16(1):137-144.
14 Sato N,Yamabuki T,Takano A,et al.Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy[J].Cancer Res,2010,70(13):5326-5336.
15 Sheng SL,Huang G,Yu B,et al.Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer[J].Clin Chem,2009,55(9):1656-1664.
16 Li S,Qin X,Guo X,et al.Dickkopf-1 is oncogenic and involved in invasive growth in non small cell lung cancer[J].PLoS One,2013,8(12):e84944.
17 Kimura H,Fumoto K,Shojima K,et al.CKAP4 is a Dickkopf1 receptor and is involved in tumor progression[J].J Clin Invest,2016,126(7):2689-2705.
18 Zhang J,Zhang X,Zhao X,et al.DKK1 promotes migration and invasion of non-small cell lung cancer via β-catenin signaling pathway[J].Tumor Biology,2017,39(7):101042831770382.
19 Xiao XJ,Liu YW,Chen DD,et al.Differential expression of Dickkopf-1 among non-small cell lung cancer cells[J].Mol Med Rep,2015,12(2):1935-1940.
20 Na Y,Lee SM,Kim DS,et al.Promoter methylation of Wnt antagonist DKK1 gene and prognostic value in Korean patients with non-small cell lung cancers[J].Cancer Biomark,2012,12(2):73-79.
21 Xu H,Wu J,Chen B,et al.Serum Dickkopf-1(DKK1)is significantly lower in patients with lung cancer but is rapidly normalized after treatment[J].Am J Transl Res,2014,6(6):850-856.
22 Dong LL,Qu LY,Chu LY,et al.Serum level of DKK-1and its prognostic potential in non-small cell lung cancer[J].Diagn Pathol,2014,9(1):52.
23 Bhavanasi D,Speer KF,Klein PS.CKAP4 is identified as a receptor for Dickkopf in cancer cells[J].J Clin Invest,2016,126(7):2419-2421.
24 Shen T,Chen Z,Qiao J,et al.Neutralizing monoclonal antibody against Dickkopf2 impairs lung cancer progression via activating NK cells[J].Cell Death Discov,2019,5:123.
25Yue W,Sun Q,Dacic S,et al.Downregulation of Dkk3 activates-catenin/TCF-4 signaling in lung cancer[J].Carcinogenesis,2008,29(1):84-92.
26 雷艳荣,张静琼,王纯.非小细胞肺癌血清DKK3基因启动子甲基化的临床意义[J].国际检验医学杂志,2013,34(11):1450-1452.
27 Li Y,Ye X,Tan C,et al.Axl as a potential therapeutic target in cancer:role of Axl in tumor growth,metastasis and angiogenesis[J].Oncogene,2009,28(39):3442-3455.
28 Sima J,Piao Y,Chen Y,et al.Molecular dynamics of Dkk4 modulates Wnt action and regulates meibomian gland development[J].Development,2016,143(24):4723-4735.
29 Patel S,Barkell AM,GuptaD,et al.Structural and functional analysis of Dickkopf 4(Dkk4):new insights into Dkk evolution and regulation of Wnt signaling by Dkk and Kremen proteins[J].J Biol Chem,2018,293(31):12149-12166.
30 Wang Z,Ma LJ,Kang Y,et al.Dickkopf-3(Dkk3)induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/β-catenin pathway[J].Oncol Rep,2015,33(3):1097-106.
31 Cheng R,Lu C,Zhang G,et al.Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1[J].Oncol Rep,2017,37(4):2129-2136.
32 Salim H,Zong D.DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines[J].BMC Cancer,2015,15(1):628.
33 Mistry SJ,Oh WK.New paradigms in microtubule-mediated endocrine signaling in prostate cancer[J].Mol Cancer Ther,2013,12(5):555-566.
34 Marzo I,Naval J.Antimitotic drugs in cancer chemotherapy:Promises and pitfalls[J].Biochem Pharmacol,2013,86(6):703-710.
35 Kuczynski EA,Sargent DJ,Grothey A,et al.Drug rechallenge and treatment beyond progression-implications for drug resistance[J].Nat Rev Clin Oncol,2013,10(10):571-587.
36 Tao L,Huang G,Chen Y,et al.DNA methylation of DKK3 modulates docetaxel chemoresistance in human nonsmall cell lung cancer cell[J].Cancer Biother Radiopharm,2015,30(2):100-106.
37 Yang X,Liu Y,Li W,et al.DKK4-knockdown enhances chemosensitivity of A549/DTX cells to docetaxel[J].Acta Biochim Biophys Sin(Shanghai),2017,49(10):899-906.
38 郭梦楠.SLL-1A-16在肺癌细胞中抗肿瘤活性及其作用机制研究[D].沈阳:辽宁大学,2019.
39 杨茜.左旋一叶萩碱诱导A549细胞株甲基化改变的研究[D].芜湖:皖南医学院,2017.
40 Papatriantafyllou M,Moldenhauer G,Ludwig J,et al.Dickkopf-3,an immune modulator in peripheral CD8 T-cell tolerance[J].Proc Natl Acad Sci U S A,2012,109(5):1631-1636.
41 Suzawa K,Shien K,Peng H,et al.Distant bystander effect of REIC/DKK3 gene therapy through immune system stimulation in thoracic malignancies[J].Anticancer Res,2017,37(1):301-308.
42 Xiao Q,Wu J,Wang W J,et al.DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation[J].Nat Med,2018,24(3):262-270.

[1]	YAN Yan, HOU Lifang, LI Renfei, YAN Peng, WANG Yuedong, ZHENG Yuting. Imaging with ^99mTc-HYNIC-MPG molecular typing of non-small cell lung cancer in vivo [J]. Journal of Practical Oncology, 2020, 34(5): 412-417.
[2]	CHEN Can, ZHANG Yanling, LIU Xiaoqing, RAN Fengwei. The effect of miR-182 on the proliferation and invasion of rectal cancer cells and regulation of Foxo3a/Wnt/β-catenin pathway [J]. Journal of Practical Oncology, 2020, 34(4): 328-333.
[3]	SUN Yajuan, JIANG Zhiyun, SHANG Naijian, SUN Qingxin, LU Peiou. Value of dual-source CT energy imaging in evaluating mediastinal lymph node metastasis in non-small cell lung cancer [J]. Journal of Practical Oncology, 2019, 33(6): 531-535.
[4]	LI Wanzhen, YIN Jun, LI Ping, LIN Xiaohui, ZHANG Guoqian, ZHANG Shuxu. The expression and role of miR-17 in radioresistant cells of non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 391-397.
[5]	CAI Jing, HOU Yue. The expression and clinical significance of serum miR-195 in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 415-419.
[6]	CUI Xiaoyan,TU Qing,GAN Jianhui. Comparison between nalbuphine and oxycodone applied for patient controlled analgesia on postoperative immunological factor levels in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 309-314.
[7]	LEI Junhua, XU Guanhua, ZENG Jiangzheng, HUANG Fen, HE Zhihui, LU Yanda. Research on JAK3/STAT3 mechanism of non-small cell lung cancer NCI-H1975 cells treated with cryptotanshinone combined with cisplatin [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 198-202.
[8]	ZHAI Keke, GAO Yuanyuan, FENG Xiao, XU Jingwen, GONG Yufang, MENG Qingwei. Analysis of first-line NSCLC chemotherapy in the phase Ⅳ patients with distant metastasis and first diagnosis after postoperative adjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 107-111.
[9]	DU Yesheng, HU Songliu, XU Xiangying. Study of oligodendrocyte metastasis in non-small cell lung cancer by stereotactic radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 154-158.
[10]	SUN Mingliang, XU Jianyu, XU Xiangying. Stereotactic radiotherapy for early stage of non - small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 53-56.
[11]	DAI Xin, ZHANG Daxin. Current status of anti-angiogenesis therapy for non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 472-476.
[12]	HU Haifeng,FENG Xiemin,QIAO Jian,DUAN Wei,LIU Ningning,SUN Xiaodong. The expression and clinical significance of miR-345 in non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 117-122.
[13]	ZHANG Rui,WANG Zhiyu,WANG Shuai,ZHAO Hui. Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diagnosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 527-522.
[14]	REN Fenghai,WANG Dandan,WANG Junfeng,XU Hai,XU Shidong. Clinical comparative study between Uniportal and single port video-assisted thoracoscopic surgery for ⅠA stage non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 327-331.
[15]	YE Leiguang, YAN An, LIU Baogang. Relationship between Aurora-A mediated drug resistance and prognosis of patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 97-102.

Research progress on the mechanism and treatment of Dickkopf family protein in non-small cell lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments